SCHEMBL3986692

SCHEMBL3986692

Cc1nn(Cc2ccc(F)cc2)c(=O)c2c(O)c3n(c12)C[C@@H]1CCCN1C3=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
NPSR1 Q6W5P4 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
HTT P42858 1/20 0.39
PKM P14618 1/20 0.38
PKLR P30613 1/20 0.38
TP53 P04637 3/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
TSHR P16473 4/20 0.37
KDM4E B2RXH2 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
USP2 O75604 1/20 0.36
SLC2A1 P11166 1/20 0.35
CNR2 P34972 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3984034 1.00 ALDH1A1 (0.39) ALDH1A1NPSR1SMN1; SMN2LMNAMAPT
SCHEMBL3983532 0.81 PKM (0.44) ALDH1A1MAPTHTTPKMPKLR
SCHEMBL3992601 0.78 KCNH2 (0.45) ALDH1A1NPSR1SMN1; SMN2LMNAPKM
SCHEMBL1384342 0.76 KCNH2 (0.41) ALDH1A1NPSR1SMN1; SMN2LMNAMAPT
SCHEMBL3983983 0.76 GRM2 (0.44) ALDH1A1LMNAMAPTPKMPKLR
SCHEMBL1384303 0.75 PKM (0.42) ALDH1A1SMN1; SMN2LMNAMAPTHTT
SCHEMBL1387122 0.74 GRM2 (0.43) ALDH1A1LMNAMAPTPKMPKLR
SCHEMBL1386743 0.73 PKM (0.39) SMN1; SMN2LMNAMAPTHTTPKM
SCHEMBL3985863 0.73 PKM (0.35) ALDH1A1SMN1; SMN2LMNAMAPTHTT
SCHEMBL13842711 0.73 PKM (0.40) SMN1; SMN2MAPTHTTPKMPKLR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP claimed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US claimed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US claimed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287394-A1 Hiv Integrase Inhibitors DHPS, DPYD, TYMP ALDH1A1 913/4885NPSR1 4295/4885SMN1; SMN2 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.